|Day's Range||135.78 - 137.81|
|52 Week Range||96.93 - 138.93|
|PE Ratio (TTM)||51.73|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene is expected to report healthy 2Q earnings thanks to its blockbuster cancer drug Revlimid.
For generic drug companies, manufacturing low-cost alternatives to brand-name medicines is the easy part. The hard part: getting their hands on the drugs they want to copy.
Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.